Researchers at Umeå University in Sweden and international collaborators have developed a fully human antibody that blocked both tumor growth and metastatic spread in preclinical models of aggressive prostate cancer through a mechanism targeting a protein pathway that drives cancer cells' ability to invade and migrate. The study was published in Signal Transduction and Targeted Therapy on June 17, 2026, and received wider attention when ScienceDaily featured the findings on July 20, 2026.
The antibody targets oncogenic signaling driven by the TGF-beta type I receptor (TbetaRI) and was able to inhibit both primary tumor growth and metastasis in models of castration-resistant prostate cancer, an aggressive form of the disease that no longer responds to hormone therapy and for which treatment options are limited.
Why This Matters
Prostate cancer is the most commonly diagnosed cancer in American men other than skin cancer. When detected and treated early, most patients do well. The danger changes sharply when cancer progresses to castration-resistant or metastatic disease, where the treatment options narrow significantly and the disease becomes far harder to control.
Approximately 35,000 American men die from prostate cancer annually, most of them from metastatic or castration-resistant disease. The currently available treatments for this stage include additional hormonal therapies, chemotherapy, targeted agents, and the radiopharmaceutical lutetium PSMA-617 (Pluvicto), which has shown efficacy but carries toxicity. New treatment approaches with different mechanisms of action are urgently needed, particularly ones that might be effective against the epithelial-to-mesenchymal transition (EMT) that allows cancer cells to escape the prostate and colonize the lymph nodes and bones.
What We Know So Far
The research team, led by Professor Maréne Landström at Umeå University, focused on a cancer-promoting event called proteolytic cleavage of TbetaRI. In castration-resistant prostate cancer cells, an enzyme called ADAM17 cleaves a portion of the TGF-beta type I receptor, releasing a soluble intracellular domain that travels to the cell nucleus and promotes the epithelial-to-mesenchymal transition, the biological process that gives cancer cells invasive properties and enables metastasis.
The research team developed fully human monoclonal antibodies that physically block this cleavage by steric hindrance, meaning the antibody attaches to the receptor in a way that prevents the enzyme from cutting it. By blocking this specific cleavage event, the antibody prevents the release of the pro-invasive intracellular domain.
In preclinical models, the antibody:
- Suppressed primary tumor growth in castration-resistant prostate cancer models
- Blocked metastatic spread to other sites
- Operated through a mechanism that the researchers proposed may have a more favorable side-effect profile than existing treatments, because it targets a specific cancer-promoting modification rather than broadly inhibiting TGF-beta signaling, which has important functions in healthy tissue
The antibody is described as "fully human," meaning it is composed entirely of human proteins, which typically reduces the risk of immune rejection and adverse reactions compared to antibodies that contain mouse-derived sequences.
An important part of the development involved collaboration with drug development experts at the SciLifeLab Drug Discovery and Development Platform, who contributed to the antibody's engineering.
Where This Research Stands
This is preclinical research: cell-line experiments and animal models. The antibody has not been tested in human subjects. No safety data, pharmacokinetics, or clinical toxicity data are available for humans. The step from preclinical efficacy in cancer cell lines and animal models to clinical approval requires years of safety evaluation, regulatory review, and human clinical trials, a process that for most cancer drugs takes 7 to 15 years from the preclinical stage.
"Further safety evaluation and regulatory assessment are required before clinical application," the MedicalXpress summary of the Umeå University press release noted.
The team has also expressed interest in exploring whether the same antibody could work against other solid tumors, since TGF-beta signaling and ADAM17-mediated cleavage play roles in several cancer types beyond prostate cancer.
What Doctors and Experts Say
"The next step is to investigate whether this treatment can also be used against other types of solid tumors. We hope that our work will ultimately contribute to the development of a new cancer drug that can benefit patients," Professor Landström said, according to MedicalXpress.
The research's framing around a "safer" mechanism requires careful interpretation. The claim is that by targeting the specific TbetaRI cleavage event rather than broadly inhibiting TGF-beta signaling, the approach may avoid some of the toxicity associated with broader TGF-beta inhibition. But this claim rests on the mechanism's theoretical specificity; actual human safety data will only come from clinical trials.
What the Evidence Shows and What It Does Not
MedicalDaily Evidence Check
- Study type: Preclinical research in castration-resistant prostate cancer cell lines and animal models
- Published in: Signal Transduction and Targeted Therapy (Nature Group); doi: 10.1038/s41392-026-02737-x; published June 17, 2026
- Institution: Umeå University, Sweden; collaborators including SciLifeLab, and international co-authors from Sweden, United Kingdom, and China (including the ICR London, per author affiliations including Johann de Bono and Jon Welti)
- Lead researcher: Professor Maréne Landström, Umeå University
- Antibody type: Fully human monoclonal antibody (composed entirely of human proteins)
- Target: Cleavage of TbetaRI (TGF-beta type I receptor) by ADAM17, which promotes EMT, invasion, and metastasis in castration-resistant prostate cancer
- Key finding: The antibody blocked TbetaRI cleavage and inhibited both primary tumor growth and metastatic spread in preclinical models
- ScienceDaily feature date: July 20, 2026
- What it shows: Proof-of-concept in preclinical models that targeting TbetaRI cleavage can inhibit aggressive prostate cancer growth and spread
- What it does not prove: That the antibody is safe or effective in humans; no human trials have been conducted
- What readers should know: This is an early-stage research finding; no clinical application is available. Patients with prostate cancer should discuss their current treatment options with their oncologist, not seek access to this experimental antibody.
Who Should Pay Attention?
This research is most directly relevant to:
- Men with castration-resistant or metastatic prostate cancer and their families, who deserve to know what new research avenues are being pursued in their disease
- Urologic oncologists and researchers working in TGF-beta biology, EMT, or drug development for prostate cancer
- Scientists at pharmaceutical companies or academic institutions evaluating novel therapeutic targets in genitourinary cancers
- Patients enrolled in or evaluating clinical trials for advanced prostate cancer
For patients currently receiving treatment, this research does not change available options.
Symptoms of Aggressive Prostate Cancer to Know
Prostate cancer in its early stages often causes no symptoms. Symptoms that may indicate disease progression include:
- Difficulty urinating or a weak or interrupted urinary stream
- Blood in the urine or semen
- Painful urination or ejaculation
- Frequent urination, especially at night
- Bone pain, particularly in the hips, back, or thighs (which may indicate metastasis to bone)
- Unexplained weight loss or fatigue
Men who have already been diagnosed with prostate cancer and notice new or worsening symptoms should contact their oncologist promptly without waiting for a scheduled appointment.
What You Can Do Now
- Men with advanced, castration-resistant, or metastatic prostate cancer who are seeking additional options should ask their oncologist about clinical trial eligibility. ClinicalTrials.gov lists active trials in advanced prostate cancer, including studies of novel mechanisms.
- Patient advocacy organizations including the Prostate Cancer Foundation and ZERO Prostate Cancer maintain updated resources on treatment options and clinical trial access for patients with advanced disease.
- Do not attempt to access this experimental antibody outside of a formal clinical trial. The drug has not been tested in humans and has no established safety profile.
- Men over 50, or over 40 with a family history or African American background (which carries higher prostate cancer risk), should discuss PSA screening with their primary care physician. Early detection remains the most effective path to curative treatment.
Cost and Access: What Patients Should Know
Existing approved treatments for castration-resistant prostate cancer, including enzalutamide, abiraterone, docetaxel, and lutetium PSMA-617 (Pluvicto), are covered by Medicare and most private insurance plans with appropriate clinical indications. Clinical trial participation typically provides experimental drugs at no cost to the patient; patients should ask their oncologist's office about trial navigator services.
What Happens Next
The Umeå University team and collaborators will pursue additional preclinical validation and potentially initiate early-phase clinical trial planning. Safety studies in animals and then Phase 1 human safety trials would be the next steps before any clinical application could be considered. MedicalDaily will report on any human trial announcement for this antibody.
The Bottom Line
A fully human antibody developed by Swedish researchers at Umeå University blocked both tumor growth and metastatic spread in preclinical models of aggressive, castration-resistant prostate cancer by targeting a specific cleavage event that drives cancer cells' invasive properties. This is early-stage preclinical work; human safety and efficacy data do not yet exist. The finding adds a novel mechanism to the research pipeline for a disease that kills approximately 35,000 American men annually. No treatment based on this research is currently available.
